Zevra Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 6/6

Zevra Therapeutics kazanç ve gelirin sırasıyla yıllık 69.7% ve 49.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 70.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 44.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

69.7%

Kazanç büyüme oranı

70.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.6%
Gelir büyüme oranı	49.4%
Gelecekteki özkaynak getirisi	44.8%
Analist kapsamı	Good
Son güncelleme	15 Oct 2024

Gelecekteki son büyüme güncellemeleri

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 04

Recent updates

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Aug 30

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors

Jul 12

Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Apr 07

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 04

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Apr 02

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Dec 28

Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

Sep 05

This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

Aug 20

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

Apr 17

US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Mar 10

Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

Mar 08

Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

Nov 16

Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

Nov 11

KemPharm posts Phase 1 data to support further studies for sleep disorder therapy

Sep 28

KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate

May 26

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:ZVRA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	179	43	26	26	7
12/31/2025	98	-18	-8	-29	8
12/31/2024	23	-75	-40	-53	8
6/30/2024	24	-67	-56	-56	N/A
3/31/2024	28	-49	-46	-46	N/A
12/31/2023	27	-46	-34	-34	N/A
9/30/2023	17	-24	-22	-22	N/A
6/30/2023	17	-17	-24	-24	N/A
3/31/2023	9	-38	-19	-19	N/A
12/31/2022	10	-27	-19	-19	N/A
9/30/2022	11	-35	-15	-15	N/A
6/30/2022	10	-30	-11	-11	N/A
3/31/2022	20	-17	9	9	N/A
12/31/2021	29	-63	10	10	N/A
9/30/2021	28	-65	10	10	N/A
6/30/2021	28	-66	12	12	N/A
3/31/2021	23	-55	-3	-3	N/A
12/31/2020	13	-13	-2	-2	N/A
9/30/2020	12	-14	-4	-4	N/A
6/30/2020	22	-8	-5	-5	N/A
3/31/2020	15	-18	-15	-15	N/A
12/31/2019	13	-25	-24	-24	N/A
9/30/2019	11	-24	-36	-36	N/A
6/30/2019	N/A	-42	-49	-49	N/A
3/31/2019	N/A	-43	-51	-51	N/A
12/31/2018	N/A	-56	-54	-54	N/A
9/30/2018	N/A	-62	-46	-46	N/A
6/30/2018	N/A	-57	-40	-40	N/A
3/31/2018	N/A	-53	N/A	-38	N/A
12/31/2017	N/A	-43	N/A	-33	N/A
9/30/2017	N/A	-43	N/A	-36	N/A
6/30/2017	N/A	-45	N/A	-34	N/A
3/31/2017	N/A	-30	N/A	-35	N/A
12/31/2016	N/A	-17	N/A	-30	N/A
9/30/2016	N/A	-16	N/A	-27	N/A
6/30/2016	N/A	-13	N/A	-23	N/A
3/31/2016	N/A	-52	N/A	-20	N/A
12/31/2015	N/A	-55	N/A	-20	N/A
9/30/2015	N/A	-57	N/A	-21	N/A
6/30/2015	N/A	-55	N/A	-20	N/A
3/31/2015	N/A	-29	N/A	-18	N/A
12/31/2014	N/A	-24	N/A	-15	N/A
9/30/2014	N/A	-14	N/A	-9	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ZVRA önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: ZVRA önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: ZVRA önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: ZVRA şirketinin gelirinin (yıllık 49.4% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ZVRA şirketinin gelirinin (yıllık 49.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ZVRA 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 44.8 %).

Zevra Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 6/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 14% to US$20.50

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased by 9.1% to US$17.50

Consensus EPS estimates fall by 50%

Forecast breakeven date pushed back to 2026

No longer forecast to breakeven

Recent updates

Zevra Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Price target increased by 14% to US$20.50

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Zevra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000005 million.

New major risk - Shareholder dilution

Zevra Therapeutics, Inc. Announces FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

New minor risk - Share price stability

Zevra Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Independent Director recently bought US$59k worth of stock

Zevra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors

Zevra Therapeutics, Inc. Expands Executive Leadership Team

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia At Sleep 2024 Annual Meeting

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zevra Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Zevra Therapeutics, Inc., Annual General Meeting, May 13, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Price target decreased by 9.1% to US$17.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 50%

Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia

Zevra Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast breakeven date pushed back to 2026

Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors

Zevra Therapeutics, Inc. Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Zevra Therapeutics, Inc. Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

No longer forecast to breakeven

Zevra Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zevra Therapeutics, Inc. Announces Executive Changes

Zevra Therapeutics, Inc. Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of Sdx, the Sole Active Pharmaceutical Ingredient in Kp1077, in Healthy Volunteers At Psych Congress 2023

Independent Director recently bought US$51k worth of stock

Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

Consensus revenue estimates increase by 18%

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Consensus revenue estimates increase by 27%

This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zevra Therapeutics, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates fall by 10%

Independent Director recently bought US$50k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zevra Therapeutics, Inc. Announces Change of CEO, Effective June 1, 2023

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

Price target decreased by 13% to US$16.80

US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

KemPharm, Inc. Appoints Daniel Gallo as Senior Vice President of Medical Affairs and Advocacy

KemPharm, Inc., Annual General Meeting, Apr 25, 2023

CEO & Director recently bought US$52k worth of stock

KemPharm, Inc. Announces Promotion of Sven Guenther to Chief Scientific Officer and Christal Mickle to Chief Product Development Officer

KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

KemPharm, Inc. Appoints Christopher Posner as New Independent Director

KemPharm, Inc. Announces That the U.S. Food and Drug Administration (The FDA) Grants the Orphan Drug Designation to Serdexmethylphenidate

Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

Kempharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (Sdx)

KemPharm posts Phase 1 data to support further studies for sleep disorder therapy

KemPharm wins Buy rating at Canaccord on CNS focus